Loading
NASDAQHealthcareBiotechnology
Latest quote
$21.24
−$1.05 · -4.71%
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Previous close
$21.24
−$1.05 · -4.71%
Regular session · ET · Market data may be delayed.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Day range
Current $21.24
52-week range
Current $21.24
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
64
Undervalued
Sentiment
76
Bullish
Risk
56
Elevated Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Day range
Current $21.24
52-week range
Current $21.24
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 70.85M USD | 302K USD | 314K USD | 1.77M USD | 2.96M USD |
| Gross profit | 70.85M USD | 302K USD | 314K USD | 1.77M USD | 2.96M USD |
| Research and development | 338.93M USD | 238.25M USD | 159.77M USD | 100.89M USD | 56.89M USD |
| Selling, general, and administrative | 95.32M USD | 61.08M USD | 95M USD | 35.18M USD | 25.81M USD |
| Operating expenses | 434.24M USD | 299.34M USD | 254.76M USD | 136.08M USD | 82.69M USD |
| Interest income | 27.4M USD | 32.13M USD | 18.56M USD | 4.92M USD | 318K USD |
| Interest expense | 4.95M USD | 3.05M USD | 1.85M USD | 486K USD | 3K USD |
| Depreciation and amortization | 460K USD | 1.24M USD | 522K USD | 255K USD | 120K USD |
| Operating income | −363.4M USD | −299.04M USD | −254.45M USD | −134.3M USD | −79.73M USD |
| Net income | −342.6M USD | −269.95M USD | −237.73M USD | −129.87M USD | −79.41M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$36.14
70.15% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI89.7M0.85%10.57B USD0.35%$156.2-0.40%
Vanguard Morningstar Total Stock Market ETFVTI63.5M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM52.09M0.07%77.55B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF21.42M0.02%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Value ETFIWN17.21M0.12%14.28B USD0.24%$219.69+0.33%
Schwab U.S. Small-Cap ETFSCHA10.52M0.05%22.32B USD0.03%$33.79+0.42%
Vanguard Russell 2000 ETFVTWO9.59M0.05%17.4B USD0.06%$116.76+0.36%
Dimensional - US Small Cap ETFDFAS7.39M0.05%15.49B USD0.26%$80.52+0.64%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
